Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Years of life lost to multiple myeloma remains high: A targeted literature review

Roberto Mina, Amruta Radhakrishnan, Anupama Vasudevan, Sandhya Sapra, Alex Bates, James Parker, Joshua Richter

Blood (2025) 146 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2025-2804

Published: 2025

Journal Articles

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

Joshua Richter, Meral Beksac, Alessandro Corso, Ollie Schofield, Dani Olivier, Leanne Cooper, Owen Harrison, Jacopo Bitetti, Benga Kazeem, Alex Bates, Natalie Boytsov, Simon McNamara, Adil Merchant, Connor Lloyd, Christina-Jane Crossman-Morgan, Nicholas Meader, Molly Purser, Nick Ballew

Blood (2025) 146 (Supplement 1): 7567.

https://doi.org/10.1182/blood-2025-7567

Published: 2025

Journal Articles

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity

Blood (2025) 146 (Supplement 1): 2290.

https://doi.org/10.1182/blood-2025-2290

Published: 2025

Journal Articles

Integrating bispecific antibodies into community myeloma care: Challenges, insights, and educational impact

Tisheeka Graham, Tariqa Ackbarali, Krina Patel, Joshua Richter

Blood (2025) 146 (Supplement 1): 8134.

https://doi.org/10.1182/blood-2025-8134

Published: 2025

Journal Articles

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Blood (2025) 146 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2025-3949

Published: 2025

Journal Articles

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Blood (2025) 146 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2025-5723

Published: 2025

Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Blood (2025) 146 (Supplement 1): 698.

https://doi.org/10.1182/blood-2025-698

Published: 2025

Journal Articles

Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers

Blood (2025) 146 (Supplement 1): 3996.

https://doi.org/10.1182/blood-2025-3996

Published: 2025

Journal Articles

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

Blood (2025) 146 (Supplement 1): 916.

https://doi.org/10.1182/blood-2025-916

Published: 2025

Journal Articles

Real-world treatment patterns and outcomes in frail and non-frail patients with newly diagnosed multiple myeloma not undergoing frontline transplant: A study using cota oncology database

Feng Lin, Samy Gallienne, Raluca Ionescu-Ittu, Yvonne Barnes, Joshua Richter

Blood (2025) 146 (Supplement 1): 6352.

https://doi.org/10.1182/blood-2025-6352

Published: 2025

Journal Articles

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2024-199519

Published: 2024

Journal Articles

Understanding Frontline Therapy Pattern, Attrition Rates and Survival Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Underwent Transplant

Feng Lin, Samy Gallienne, Raluca Ionescu-Ittu, Medha Sasane, Ani Minasyan, Christina Tekle, Joshua Richter

Blood (2024) 144 (Supplement 1): 3761.

https://doi.org/10.1182/blood-2024-201296

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Frontline Treatment Patterns and Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Did Not Undergo Transplant: A US Electronic Health Records Database Analysis

Feng Lin, Samy Gallienne, Raluca Ionescu-Ittu, Medha Sasane, Ani Minasyan, Christina Tekle, Joshua Richter

Blood (2024) 144 (Supplement 1): 5138.

https://doi.org/10.1182/blood-2024-201260

Published: 2024

Journal Articles

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Paula Rodríguez-Otero, Joshua Richter, Ajay K. Nooka, Fredrik Schjesvold, Emily Combe, Leanne Cooper, Ollie Schofield, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Simon McNamara, Molly Purser

Blood (2024) 144 (Supplement 1): 7054.

https://doi.org/10.1182/blood-2024-198712

Published: 2024

Journal Articles

A Phase 2 Study of Daratumumab in Combination with Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

Larysa J Sanchez, Erin Moshier, Alex Lieberman-Cribbin, Joshua Richter, Shambavi Richard, Adriana Rossi, Cesar Rodriguez, Santiago Thibaud, Hearn Jay Cho, Samir Parekh, Sundar Jagannath, Ajai Chari

Blood (2024) 144 (Supplement 1): 7043.

https://doi.org/10.1182/blood-2024-211704

Published: 2024

Journal Articles

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Zachary M Avigan, Saoirse Bodnar, Darren Pan, Adolfo Aleman, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana Rossi, Shambavi Richard, Hearn Jay Cho, Sundar Jagannath, Samir Parekh, Santiago Thibaud

Blood (2024) 144 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2024-202725

Published: 2024

Journal Articles

In- class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

Joshua Richter, Saulius Girnius, Ruemu Birhiray, Eric Lloyd, Dasha Cherepanov, Stephen J. Noga, Isabel Nascimento-Ferreira, Robert Rifkin

Blood (2024) 144 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2024-194592

Published: 2024

Journal Articles

Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Saoirse Bodnar, Tehilla Brander, Zachary M Avigan, William Genthe, David Melnekoff, Alessandro Lagana, Jane Houldsworth, Shambavi Richard, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana Rossi, Hearn Jay Cho, Kenan Onel, Sundar Jagannath, Manisha Balwani, Samir Parekh, Santiago Thibaud

Blood (2024) 144 (Supplement 1): 1970.

https://doi.org/10.1182/blood-2024-212204

Published: 2024

Journal Articles

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Blood (2024) 144 (Supplement 1): 357.

https://doi.org/10.1182/blood-2024-204929

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Years of life lost to multiple myeloma remains high: A targeted literature review

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity

Integrating bispecific antibodies into community myeloma care: Challenges, insights, and educational impact

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

Real-world treatment patterns and outcomes in frail and non-frail patients with newly diagnosed multiple myeloma not undergoing frontline transplant: A study using cota oncology database

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Understanding Frontline Therapy Pattern, Attrition Rates and Survival Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Underwent Transplant

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Frontline Treatment Patterns and Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Did Not Undergo Transplant: A US Electronic Health Records Database Analysis

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

A Phase 2 Study of Daratumumab in Combination with Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

In- class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only